Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Controlled Phase Ⅳ Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine in Healthy Infants Aged 8 ~12 Months.

NCT04364399 is registered in ClinicalTrials.gov with Sinovac (Dalian) Vaccine Technology Co., Ltd. as lead sponsor.

NCT NCT04364399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04364399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Controlled Phase Ⅳ Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine in Healthy Infants Aged 8 ~12 Months.
Lead sponsor
Sinovac (Dalian) Vaccine Technology Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
November 18, 2020
Completion date
April 7, 2021
Enrollment
920 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mumps